Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors. Issue 8 (26th April 2017)

• Record Type: Journal Article
• Authors: Kyriakidis, Ioannis; Tragiannidis, Athanasios; Zündorf, Ilse; Groll, Andreas H.
• Is Part Of: Mycoses. Volume 60:Issue 8(2017)
• Page Start: 493
• Page End: 507
• Publication Date: 2017-04-26
• Subjects: alemtuzumab -- basiliximab -- daclizumab -- monoclonal antibodies -- Pneumocystis -- rituximab; Pathogenic fungi -- Periodicals; Medical mycology -- Periodicals; 616.969
• DOI: 10.1111/myc.12621
• Languages: English
• ISSNs: 0933-7407

Abstract

Summary: An expanding list of immunomodulatory or immunosuppressive monoclonal antibodies (mAbs) and biologic therapeutics is currently entering clinical practice, particularly in the areas of oncology, transplantation and autoimmune disorders. These agents are directed against molecules or cells involved in inflammation and immunity and may therefore be associated with serious and opportunistic infections. The purpose of this review was to critically analyse the literature on invasive fungal infections (IFIs) occurring in association with mAbs and fusion proteins other than tumour necrosis alpha (TNF‐α) inhibitors, including therapeutics modulating T‐cell‐mediated pathologies (muromonab, abatacept, belatacept, ipilimumab, basiliximab, daclizumab), inducing lymphopenia (alemtuzumab), depleting CD20+ B cells (rituximab) and interfering with various targets (anakinra, natalizumab, blodalumab, ixekizumab and others) with a focus on children, and to provide a framework of evaluating the risk for IFIs in this population.